From: Microvascular alterations in patients with SARS-COV-2 severe pneumonia
Male (n, %) | 10 (83.3%) |
Age (years) | 56 (10) |
BMI (kg/m2) | 31.6 (5.4) |
Comorbidities (n, %) | |
Dyslipidemia | 4 (33.3%) |
Hypertension | 3 (25.0%) |
Diabetes type 2 | 2 (16.7%) |
Ischemic cardiomyopathy | 2 (16.7%) |
Tidal volume (ml) | 421 (190) |
RR (breath/min) | 13 (3) |
Pplat (cmH2O) | 27 (5) |
PEEP (cmH2O) | 10 (8.6; 13.8) |
∆P (cmH2O) | 13 (4) |
Cstat (ml/cmH2O) | 52 (37) |
FiO2 | 0.40 (0.35; 0.48) |
PaO2/FiO2 (mmHg) | 207 (88) |
VV-ECMO (n, %) | 6 (50.0%) |
CRRT (n, %) | 2 (16.7%) |
MAP (mmHg) | 88 (13) |
HR (beat/min) | 86 (23) |
Lactate (mmo/l) | 1.16 (0.41) |
WBC (×109/l) | 14.12 (5.13) |
IL-6 (pg/ml) | 138 (18.5; 338) |
D-Dimer (ng/ml) | 788 (717; 5536) |
Noradrenaline | |
n (%) | 9 (75%) |
mcg/kg/min | 0.24 (0.14) |
Propofol | |
n (%) | 9 (75%) |
mg/kg/h | 2.5 (0.46) |
Midazolam | |
n (%) | 9 (75%) |
mg/kg/h | 0.26 (0.12) |
Remifentanil | |
n (%) | 12 (100%) |
mcg/kg/min | 0.1 (0.85; 0.1) |